Gennex Laboratories Ltd

Dematerialisation status

• Dematerialisation requests processed; confirmations were issued to the depository.
• Dematerialised securities listed on the stock exchanges where existing securities are listed.
• Physical certificates dematerialised were mutilated and cancelled; registered owner updated within 15 days.

Appointment of Independent Director: Dipankar Dasgupta

• Type: Appointment of Dipankar Dasgupta as Independent (Non-Executive) Director.
• Effective from October 01, 2026; term: Independent (Non-Executive) Director.
• Reason: Appointment approved by AGM; not related to promoter.
• Profile: 35+ years in finance and management; B.Com; CA (Inter).
• Relationship disclosures: Not related to Directors or KMP.

Retirement of Independent Director: Amudala Sreeramulu Nageswar Rao

• Type: Retirement of Independent Director.
• Name: Amudala Sreeramulu Nageswar Rao, Independent Director.
• Date of cessation: September 30, 2026.
• Reason: Completion of first term as Independent Director.

Gennex Laboratories Limited — Trading window closed from October 01, 2026 till 48 hours after the public announcement of the Unaudited Standalone and Consolidated Financial Results for the Second Quarter and Half Year ended September 30, 2026

AP DCA approvals for Deccan Remedies

• Deccan Remedies Limited received AP DCA approval for additional items under Form 25 license No.31/VP/AP/2014/B/R/CC, valid to 28.05.2028.
• Six products approved under Form 25 may be manufactured and sold domestically and for export.
• Form 25 license valid until 28 May 2028.
• Form-29 test license granted for Ranolazine, Cinnarizine, Sacubitril, Triclabendazole; valid for three years.
• Test license permits examination, test or analysis; not for medical use; labels indicate Not for medical use.
• Three-year validity begins from date of issue.

Financial performance

• Standalone revenue from operations rose to 11,985.67 Lakhs from 9,457.79.
• Consolidated revenue from operations stood at 17,274.09 Lakhs.
• Standalone total income reached 12,799.68 Lakhs.
• Standalone PAT: 1,612.81 Lakhs; EPS: 0.666.
• Consolidated PAT: 2103.07 Lakhs; Consolidated EPS: 0.866.
• No dividend recommended for the year.

Capital structure

• Authorized share capital Rs 25 crore remains unchanged.
• Issued & subscribed equity shares: 239,854,500.
• Paid-up capital as at 31-03-2026: Rs 24.29 crore.
• Warrants converted into equity during the year.

Governance

• Shilpa Bung resigned as Independent Director on 14-02-2026.
• Khushbu Kachhawa appointed Independent Woman Director on 14-02-2026.
• Dipankar Dasgupta appointed Independent Director from 01-10-2026 for five-year term.
• Dr Avasarala Pantulu retires by rotation; re-appointment proposed.
• Statutory Auditors: M/s. R Pugalia & Company; Secretarial Auditor: Md Tausif Shamim.
• Audit Committee meetings held; composition updated after February 2026.

AGM & governance

• 41st AGM via VC/OAVM on September 30, 2026.
• Remote e-voting window: Sept 27-29, 2026; cut-off date Sept 23, 2026.
• Notice hosted on the company website; NSDL e-voting facility.

Audit & internal controls

• Independent Auditor's Report notes need for Transaction Traceability Software; management evaluating vendors.
• Internal controls are adequate; quarterly reviews by Audit Committee.
• Secretarial Audit: Md Tausif Shamim; Form MR-3 annexed.

Operations & strategy

• Expansion plans underway; production capacity and R&D to manufacture additional APIs.
• Management evaluating financing options to fund capex and growth.
• Subsidiary Deccan Remedies Limited supports expansion efforts.

CSR & related parties

• CSR obligation Rs 746.70 Lakh; Actual spend Rs 760 Lakh; carry forward Rs 713.29 Lakh.
• Related party transactions at arm's length and in ordinary course.
• CSR policy aligned with Schedule VII.

Risks & outlook

• Outlook positive with expected growth in sales and profitability.
• Risks include regulatory changes, global pharma competition, and currency exposure.

Meeting Details

• Board to meet on Sep 04, 2026 at 04:00 PM at Hyderabad corporate office.

Key Agenda Items

• Decide on conduct of the 41st AGM for year ended March 31, 2026.
• Consider and appoint Scrutinizer for AGM if date finalised.
• Any other business with permission of the Chairperson.

Other Notes

• Intimation uploaded on company website.

Consolidated Q1 FY27

• Consolidated Revenue from Operations: Rs 3,984.17 lakh.
• Consolidated Total Income: Rs 4,184.99 lakh.
• Consolidated Net Profit after Tax: Rs 466.64 lakh.
• Consolidated PBT: Rs 491.64 lakh.
• Consolidated EPS: Rs 0.163 (basic/diluted).
• Consolidated tax expense: Rs 25.00 lakh.
• Segment: Bulk Drugs, Biotech Products & Intermediates.

Standalone Q1 FY27

• Standalone Revenue from Operations: Rs 3,467.79 lakh.
• Standalone Total Income: Rs 3,667.49 lakh.
• Standalone Net Profit after Tax: Rs 395.53 lakh.
• Standalone EPS: Rs 0.163.

Geography & Segment

• Single reportable segment: Bulk Drugs, Biotech Products and Intermediates.
• India quarterly revenue: Rs 2,537.08 lakh.
• Colombia quarterly revenue: Rs 350.60 lakh.
• Egypt quarterly revenue: Rs 253.58 lakh.
• Vietnam quarterly revenue: Rs 81.72 lakh.
• Mexico quarterly revenue: Rs 37.65 lakh.
• Total quarterly revenue by country: Rs 3,467.79 lakh.

Board actions & notes

• Board approved unaudited standalone and consolidated results for quarter ended 30 Jun 2026.
• Limited review reports by statutory auditors on standalone and consolidated results.
• One reportable segment; prior periods regrouped.
• Subsidiary Deccan Remedies Ltd included in consolidated results.